Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt–Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia
International Journal of Molecular Sciences · 08.05.2024 · 25 (10) · 5106
DOI: 10.3390/ijms25105106 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.05.2024. Verfasst von Giuseppe Mario Bentivenga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, 40139 Bologna, Italy. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome, Glial Fibrillary Acidic Protein, tau Proteins, Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministero della Salute (“Ricerca Corrente”).
Themen: Demenz
Abstract (Originalsprache)
The diagnostic and prognostic value of plasma glial fibrillary acidic protein (pl-GFAP) in sporadic Creutzfeldt–Jakob disease (sCJD) has never been assessed in the clinical setting of rapidly progressive dementia (RPD). Using commercially available immunoassays, we assayed the plasma levels of GFAP, tau (pl-tau), and neurofilament light chain (pl-NfL) and the CSF total tau (t-tau), 14-3-3, NfL, phospho-tau181 (p-tau), and amyloid-beta isoforms 42 (Aβ42) and 40 (Aβ40) in sCJD (n = 132) and non-prion RPD (np-RPD) (n = 94) patients, and healthy controls (HC) (n = 54). We also measured the CSF GFAP in 67 sCJD patients. Pl-GFAP was significantly elevated in the sCJD compared to the np-RPD and HC groups and affected by the sCJD subtype. Its diagnostic accuracy (area under the curve (AUC) 0.760) in discriminating sCJD from np-RPD was higher than the plasma and CSF NfL (AUCs of 0.596 and 0.663) but inferior to the 14-3-3, t-tau, and pl-tau (AUCs of 0.875, 0.918, and 0.805). Pl-GFAP showed no association with sCJD survival after adjusting for known prognostic factors. Additionally, pl-GFAP levels were associated with 14-3-3, pl-tau, and pl-NfL but not with CSF GFAP, Aβ42/Aβ40, and p-tau. The diagnostic and prognostic value of pl-GFAP is inferior to established neurodegeneration biomarkers. Nonetheless, pl-GFAP noninvasively detects neuroinflammation and neurodegeneration in sCJD, warranting potential applications in disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, 40139 Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
ORCID-Profile: Simone Baiardi, Sabina Capellari, Piero Parchi
Förderung
- Ministero della Salute
- Italian Ministero della Salute (“Ricerca Corrente”)
Zitieren
APA
Bentivenga, G. M., Baiardi, S., Mastrangelo, A., Zenesini, C., Mammana, A., Rossi, M., Polischi, B., Capellari, S., & Parchi, P. (2024). Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt–Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia. International Journal of Molecular Sciences, 25(10), 5106. https://doi.org/10.3390/ijms25105106
Vancouver
Bentivenga GM, Baiardi S, Mastrangelo A, Zenesini C, Mammana A, Rossi M, et al. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt–Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia. International Journal of Molecular Sciences. 2024;25(10):5106. doi:10.3390/ijms25105106
BibTeX
@article{Bentivenga2024,
author = {Bentivenga, Giuseppe Mario and Baiardi, Simone and Mastrangelo, Andrea and Zenesini, Corrado and Mammana, Angela and Rossi, Marcello and Polischi, Barbara and Capellari, Sabina and Parchi, Piero},
title = {Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt–Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5106},
doi = {10.3390/ijms25105106}
}
EUVIMED